Holdings A/S Novo - Jun 22, 2021 Form 4 Insider Report for Cyteir Therapeutics, Inc. (CYT)

Role
10%+ Owner
Signature
/s/ Peter Haahr, Chief Financial Officer of Novo Holdings A/S
Stock symbol
CYT
Transactions as of
Jun 22, 2021
Transactions value $
$4,999,986
Form type
4
Date filed
6/23/2021, 05:18 PM
Previous filing
Jun 22, 2021
Next filing
Oct 21, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYT COMMON STOCK Conversion of derivative security +4.56M 4.56M Jun 22, 2021 Direct F1
transaction CYT COMMON STOCK Purchase $5M +278K +6.09% $18.00 4.84M Jun 22, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYT SERIES B CONVERTIBLE PREFERRED STOCK Conversion of derivative security -14M -100% 0 Jun 22, 2021 COMMON STOCK 4.11M Direct F1
transaction CYT SERIES C CONVERTIBLE PREFERRED STOCK Conversion of derivative security -1.55M -100% 0 Jun 22, 2021 COMMON STOCK 456K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of common stock, based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock, upon the completion of the Issuer's initial public offering. These shares have no expiration date.
F2 Represents a purchase from the underwriters in the Issuer's initial public offering.